Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

Akeso announced that AK158D1, an investigational next-generation bispecific antibody-drug conjugate targeting EGFR and TROP2, received clearance to begin Phase I clinical trials from the Center for Drug Evaluation. The clearance advances Akeso's oncology pipeline, but the asset remains at an early clinical stage and efficacy, safety, and commercial prospects are unproven.